AI assistant
Evotec SE — Regulatory Filings 2012
Jan 11, 2012
151_rns_2012-01-11_2c46b2a8-bb29-403a-88af-18716d432615.html
Regulatory Filings
Open in viewerOpens in your device viewer
News Details
Corporate | 11 January 2012 07:28
Evotec Receives 4th Milestone Payment in 2011 as Part of its Discovery Alliance with Boehringer Ingelheim
Evotec AG / Key word(s): Alliance
11.01.2012 / 07:28
Hamburg, Germany - 11 January 2012: Evotec AG (Frankfurt Stock Exchange:
EVT, TecDAX) today announced that its research alliance with Boehringer
Ingelheim has achieved a milestone triggering a payment of EUR 2.5 million
to Evotec. The milestone was achieved for the identification and selection
of a compound to be advanced into extended profiling prior to pre-clinical
development within an oncology programme. This is the fourth milestone
achieved in 2011 and represents a total of EUR 10.5 million of milestones
achieved within the year.
Dr Mario Polywka, Chief Operating Officer of Evotec commented: 'This is the
fifth milestone achieved against an oncology target within our
collaboration with Boehringer Ingelheim. Evotec values this collaboration
very highly and both companies continue to enjoy a fruitful scientific and
working relationship as we drive important new drug candidates to the
clinic.'
ABOUT THE EVOTEC & BOEHRINGER INGELHEIM ALLIANCE
In 2004, Evotec entered into a multi-year, multi-target drug discovery
alliance with Boehringer Ingelheim to jointly identify and develop
preclinical development candidates for the treatment of various disease
areas including CNS, inflammation, cardiometabolic and respiratory
diseases. In 2009, the collaboration was extended for an additional four
years and the scope expanded to include oncology targets. Under the terms
of the agreement, Boehringer Ingelheim has full ownership and global
responsibility for clinical development, manufacturing and
commercialisation of the compounds identified. In return, Evotec receives
ongoing research payments and preclinical milestones. Furthermore, the
contract provides substantial long-term upside for Evotec through potential
payments for successful milestone achievements during clinical development
and royalties when new drugs reach the market.
Contact Evotec AG:
Dr Werner Lanthaler, Chief Executive Officer, Phone: +49.(0)40.56081-242,
[email protected]
End of Corporate News
11.01.2012 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
Language: English
Company: Evotec AG
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
E-mail: [email protected]
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, Hamburg, Hannover,
München, Stuttgart
End of News DGAP News-Service
152285 11.01.2012